-Participants with SR-aGVHD disease achieved 67% ORR and 17% CR as measured by best response-
-Participants with TR-aGVHD (11 of 12 concurrent with ruxolitinib) achieved 67% ORR and 25% CR at Day 28-
-Median survival benefits in TR-aGVHD participants compared to historical controls favorable
Neihulizumab was well tolerated, with safety profiles similar to those observed when given alone or in combination with ruxolitinib.
SAN FRANCISCO, Dec. 10, 2022 (GLOBE NEWSWIRE) — AltruBio Inc. (“AltruBio” or “the Company”), a clinical-stage biotechnology company focused on the development of novel therapeutics to treat immunological diseases with high unmet medical need, today announced the presentation of new data from its completed Phase 1b clinical trial -Study known ALTB-168 in patients with steroid-refractory (SR-aGVHD) or treatment-refractory (TR-aGVHD) acute graft-versus-host disease at 64th American Society of Hematology (ASH) Annual Meeting to be held December 10-13, 2022 in New Orleans, La. Cancer Center, Hospital Frödtert Medical.
“The promising efficacy, positive safety and tolerability of ALTB-168 is very encouraging, particularly in this patient population who have minimal treatment options,” said Dr. Sameem Abedin, MD, Assistant Professor, Medical College of Wisconsin, Cancer Center, Froedtert Hospital Medical , and a principal investigator participating in the clinical study. “60% of patients with aGVHD do not respond to corticosteroids as first-line treatment, and those who do not respond to treatment have extremely poor outcomes. There is an urgent need to provide effective and long-lasting treatment options with fewer side effects. “
Jesse Hall, MD, AltruBio’s Chief Medical Officer, added, “We are pleased to share efficacy data demonstrating that treatment with an immune checkpoint enhancer…
[ad_2]
Source story
